Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

IAP (inhibitor of apoptosis protein)

3 abstracts

Abstract
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Org: University of Pittsburgh Medical Center, University of Birmingham, Dana-Farber Cancer Institute, National Cancer Center Hospital East, Kashiwa, Japan, UCSF Medical Center-Mount Zion,
Abstract
Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.
Org: EMD Serono Research & Development Institute, Merck,
Abstract
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Org: EMD Serono Research & Development Institute, Debiopharm, Merck,